Abstract
This study aimed to evaluate the efficacy and safety of transarterial infusion of programmed cell death receptor-1 (PD-1) antibody therapy in advanced or metastatic acral and mucosal melanomas. Eleven patients with acral or mucosal melanoma were referred to the department of Internal Medicine-Oncology in Huazhong University of Science and Technology Union Shenzhen Hospital from January 2019 to August 2020. These patients received transarterial infusions of PD-1 antibody and intravenous infusions of albumin-bound paclitaxel. The median duration of follow-up was 8 months. The patients were treated with transarterial infusion of PD-1 antibody and intravenous infusion of albumin-bound paclitaxel. in study, We collected and recorded immunotherapy-related adverse events. The results showed that the response rate (RR) and the disease control rate (DCR) of the patients (seven with acral melanoma, four with mucosal melanoma) were 54.5 % and 90.9 %, respectively. No grade 3-4 adverse events or major complications were observed during the study. The median progression-free survival was 10 months. The transarterial infusion of PD-1 antibody has remission and control effects on acral and mucosal melanomas, which is important for the clinical care of these patients.
Highlights
This study aimed to evaluate the efficacy and safety of transarterial infusion of programmed cell death receptor-1 (PD-1) antibody therapy in advanced or metastatic acral and mucosal melanomas
The results showed that the response rate (RR) and the disease control rate (DCR) of the patients were 54.5 % and 90.9 %, respectively
In Western this study aimed to evaluate the efficacy and safety of countries, skin melanoma is predominant, accounting transarterial infusion of anti-PD-1 in the treatment of for approximately 90 % of cases, while the acral and advanced or metastatic acral and mucosal melanomas, mucosa types are predominant in China, accounting in order to develop reference values for the clinical for 41.8 % and 22.6 %, respectively [2,3,4]
Summary
This study aimed to evaluate the efficacy and safety of transarterial infusion of programmed cell death receptor-1 (PD-1) antibody therapy in advanced or metastatic acral and mucosal melanomas. The pathological types and biological clinical data regarding anti-PD-1 treatment characteristics of melanoma in China are different by arterial perfusion are very rare [8,9,10,11] In Western this study aimed to evaluate the efficacy and safety of countries, skin melanoma is predominant, accounting transarterial infusion of anti-PD-1 in the treatment of for approximately 90 % of cases, while the acral and advanced or metastatic acral and mucosal melanomas, mucosa types are predominant in China, accounting in order to develop reference values for the clinical for 41.8 % and 22.6 %, respectively [2,3,4].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Cellular and molecular biology (Noisy-le-Grand, France)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
